tiprankstipranks
ABIONYX Pharma SA (GB:0RAG)
LSE:0RAG

ABIONYX Pharma SA (0RAG) Price & Analysis

Compare
0 Followers

0RAG Stock Chart & Stats


---

Financials

Quarterly

0RAG FAQ

What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €0.92 and its highest was €1.44 in the past 12 months.
    What is ABIONYX Pharma SA’s market cap?
    ABIONYX Pharma SA’s market cap is €42.82M.
      When is ABIONYX Pharma SA’s upcoming earnings report date?
      ABIONYX Pharma SA’s upcoming earnings report date is Mar 06, 2025 which is in 14 days.
        How were ABIONYX Pharma SA’s earnings last quarter?
        ABIONYX Pharma SA released its earnings results on Sep 26, 2024. The company reported -€0.065 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.065.
          Is ABIONYX Pharma SA overvalued?
          According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does ABIONYX Pharma SA pay dividends?
            ABIONYX Pharma SA does not currently pay dividends.
            What is ABIONYX Pharma SA’s EPS estimate?
            ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does ABIONYX Pharma SA have?
            ABIONYX Pharma SA has 34,931,010 shares outstanding.
              What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
              ABIONYX Pharma SA reported an EPS of -€0.065 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of ABIONYX Pharma SA?
                Currently, no hedge funds are holding shares in GB:0RAG
                ---

                Company Description

                ABIONYX Pharma SA

                ABIONYX Pharma SA is a biopharmaceutical company, which engages in discovery and development of novel therapies based on high-density lipoproteins and the metabolism of lipids for the treatment of associated cardiovascular and metabolic diseases. Its therapies consist of CER 001 and 209. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Labege, France.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Innate Pharma SA
                Virbac SA
                Cellectis SA
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis